CurrentCignaPolicy IP0320

Imbruvica for Non-Oncology Uses

Cigna drug coverage policy defining prior authorization and medical necessity criteria for Imbruvica when used for non-oncology indications, with explicit FDA-approved chronic graft-versus-host disease criteria and exclusion of other non-oncology uses.

Policy Summary

PayerCigna

PolicyImbruvica for Non-Oncology Uses

Policy CodePolicy IP0320

Change TypeRevisedAdded

Effective DateSep 1, 2025

Next Review Date

Key ActionPrior Authorization is required for benefit coverage of Imbruvica; document that the patient has tried at least one systemic medication for graft-versus-host disease to meet medical necessity.

SourceLink

POLICY UPDATE CHANGES

Updated conventional systemic treatment criteria from 'inadequate response..unless contraindicated or intolerant' to 'tried'.

Updated title from 'Ibrutinib for Non-Oncology Uses' to 'Imbruvica for Non-Oncology Uses'.

Added Rezurock (belumosudil), Niktimvo (axatilimab-csfr), hydroxychloroquine, rituximab, pentostatin, interleukin-2, cyclosporine, tacrolimus, sirolimus, and an etanercept product to examples of systemic medications.

1Covered Non-Oncology Indications (per policy)

All othersNon-oncology uses considered not medically necessary

1 yearApproval Duration for cGVHD when criteria met

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Cigna's drug coverage policy (Policy Number IP0320, effective 2025-09-01, last reviewed 2025-09-01) addresses Imbruvica (ibrutinib) when used for non-oncology indications. The policy defines prior authorization and medical necessity criteria, explicitly aligning coverage with the FDA-approved chronic graft-versus-host disease (cGVHD) indication and relevant guideline recommendations. Imbruvica is covered for cGVHD when the policy criteria are met; other non-oncology uses are considered not medically necessary.

Key Policy Facts

Policy IdentifierIP0320

Effective Date2025-09-01

Last Review2025-09-01

Approval Duration for cGVHD1 year (approve if criteria met)

Coverage StanceMixed — FDA‑approved for chronic graft‑versus‑host disease; other non‑oncology uses not medically necessary

Medical Necessity — Initial Therapy

Medical Necessity — FDA-Approved Indication: Chronic Graft-Versus-Host Disease (cGVHD)

Approve for 1 year if the patient meets BOTH of the following (A and B):

ALL of the following

A: Patient is ≥ 1 year of age
B: Patient has tried at least one systemic medication for graft-versus-host disease
Examples of systemic medications include: corticosteroids (methylprednisolone, prednisone), imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, Jakafi (ruxolitinib tablets), Rezurock (belumosudil tablets), Niktimvo (axatilimab-csfr intravenous infusion), hydroxychloroquine, rituximab, pentostatin, interleukin-2 (e.g., Proleukin [aldesleukin intravenous infusion]), cyclosporine, tacrolimus, sirolimus, an etanercept product.

Continuation / Duration

When the cGVHD criteria are met, Imbruvica approvals are provided for a duration of 1 year. Prior authorization is required and all approvals are issued for the duration noted in the policy.

Not Medically Necessary / Exclusions

Not Medically Necessary

Imbruvica for any other non-oncology use is considered not medically necessary.

ANY of the following

Any non-oncology indication other than chronic graft-versus-host disease as defined above

Applicable Codes

Policy Identifiermixed

IP0320

Coverage Policy Number

Provider Actions & Billing

Prior Authorization

Prior authorization required

Prior Authorization is required for benefit coverage of Imbruvica. Approvals are provided for the duration noted (e.g., 1 year for chronic graft-versus-host disease when criteria are met).

Documentation Required

Documentation of prior systemic therapy

Provider must document that the patient has tried at least one systemic medication for graft-versus-host disease to meet medical necessity. Examples of systemic medications listed in the policy include: corticosteroids (methylprednisolone, prednisone), imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, Jakafi (ruxolitinib tablets), Rezurock (belumosudil tablets), Niktimvo (axatilimab-csfr intravenous infusion), hydroxychloroquine, rituximab, pentostatin, interleukin-2 (e.g., Proleukin [aldesleukin intravenous infusion]), cyclosporine, tacrolimus, sirolimus, and an etanercept product.

Clinical Evidence & References

Evidence cited includes the FDA Prescribing Information for Imbruvica (tablets, capsules, and oral solution – December 2024) and multiple NCCN guideline versions (2024–2025) referenced for B-cell lymphomas, CNS cancers, CLL/SLL, graft-versus-host disease, Waldenström macroglobulinemia, and related indications. The policy background states it aligns coverage with the FDA-approved cGVHD indication and NCCN guideline recommendations.

Background

Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor with multiple oncology indications (for example, CLL/SLL, mantle cell lymphoma, and Waldenström macroglobulinemia). This policy specifically addresses non-oncology uses by aligning coverage with the FDA-approved indication for chronic graft-versus-host disease and incorporating guideline recommendations into medical necessity criteria.

Definition — Systemic medication for graft-versus-host disease: medications listed as examples in the policy, including corticosteroids (methylprednisolone, prednisone), imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, ruxolitinib (Jakafi), belumosudil (Rezurock), axatilimab-csfr (Niktimvo), hydroxychloroquine, rituximab, pentostatin, interleukin-2 (e.g., Proleukin), cyclosporine, tacrolimus, sirolimus, and etanercept products.

Revision History

9/15/2024revised

Reworded conventional systemic treatment criteria from 'inadequate response..unless contraindicated or intolerant' to 'tried' (changed phrasing to require the patient has tried at least one systemic medication).

9/15/2024revised

Administrative title change: updated policy title from 'Ibrutinib for Non-Oncology Uses' to 'Imbruvica for Non-Oncology Uses'.

9/1/2025addedLatest